LLY

1,160.54

+2.98%↑

JNJ

231.81

+2.07%↑

ABBV

228.08

+3.32%↑

UNH

401.09

+0.74%↑

MRK

122

+2.94%↑

LLY

1,160.54

+2.98%↑

JNJ

231.81

+2.07%↑

ABBV

228.08

+3.32%↑

UNH

401.09

+0.74%↑

MRK

122

+2.94%↑

LLY

1,160.54

+2.98%↑

JNJ

231.81

+2.07%↑

ABBV

228.08

+3.32%↑

UNH

401.09

+0.74%↑

MRK

122

+2.94%↑

LLY

1,160.54

+2.98%↑

JNJ

231.81

+2.07%↑

ABBV

228.08

+3.32%↑

UNH

401.09

+0.74%↑

MRK

122

+2.94%↑

LLY

1,160.54

+2.98%↑

JNJ

231.81

+2.07%↑

ABBV

228.08

+3.32%↑

UNH

401.09

+0.74%↑

MRK

122

+2.94%↑

Home・Aktien・Cerus Corp

Cerus Corp

Geschlossen

BrancheGesundheitswesen

2.78 4.91

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

2.66

Max

2.83

Schlüsselkennzahlen
By Trading Economics
Einkommen	527K -1.6M
Verkäufe	2.1M 60M
EPS	-0.01
Gewinnspanne	-2.752
Angestellte	261
EBITDA	1.9M 93K

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+61.29% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	4. Aug. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	172M 569M
Vorheriger Eröffnungskurs	-2.13
Vorheriger Schlusskurs	2.78

Nachrichtenstimmung

By Acuity

50%

155 / 344 Ranking in Healthcare

Cerus Corp Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Peer-Vergleich

Kursveränderung

Cerus Corp Prognose

Kursziel

By TipRanks

61.29% Vorteil

12-Monats-Prognose

Durchschnitt 4.5 USD 61.29%

Hoch 5 USD

Tief 4 USD

Basierend auf 3 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Cerus Corp – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

3 ratings

Buy

Halten

Sell

Basierend auf 3 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Cerus Corp – Dist abgegeben haben.

Stimmung

By Acuity

155 / 344 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Cerus Corp

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.